118 related articles for article (PubMed ID: 26009225)
1. Bivalirudin versus heparin use for patients undergoing PPCI.
Miyasaka M; Wada Y; Kami M
Lancet; 2015 May; 385(9982):2044-5. PubMed ID: 26009225
[No Abstract] [Full Text] [Related]
2. Bivalirudin versus heparin use for patients undergoing PPCI.
Shah R
Lancet; 2015 May; 385(9982):2045. PubMed ID: 26009227
[No Abstract] [Full Text] [Related]
3. Bivalirudin versus heparin use for patients undergoing PPCI.
Schneider DJ
Lancet; 2015 May; 385(9982):2044. PubMed ID: 26009224
[No Abstract] [Full Text] [Related]
4. Bivalirudin versus heparin use for patients undergoing PPCI.
Steg PG; van't Hof AW; Zeymer U; Goldstein P
Lancet; 2015 May; 385(9982):2043-4. PubMed ID: 26009223
[No Abstract] [Full Text] [Related]
5. Bivalirudin versus heparin use for patients undergoing PPCI - Authors' reply.
Shahzad A; Stables RH
Lancet; 2015 May; 385(9982):2045-6. PubMed ID: 26009226
[No Abstract] [Full Text] [Related]
6. Is the heat on HEAT-PPCI appropriate?
Berger PB; Blankenship JC
Lancet; 2014 Nov; 384(9957):1824-1826. PubMed ID: 25002176
[No Abstract] [Full Text] [Related]
7. HEAT-PPCI sheds light on consent in pragmatic trials.
Shaw D
Lancet; 2014 Nov; 384(9957):1826-1827. PubMed ID: 25002175
[No Abstract] [Full Text] [Related]
8. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.
Shahzad A; Kemp I; Mars C; Wilson K; Roome C; Cooper R; Andron M; Appleby C; Fisher M; Khand A; Kunadian B; Mills JD; Morris JL; Morrison WL; Munir S; Palmer ND; Perry RA; Ramsdale DR; Velavan P; Stables RH;
Lancet; 2014 Nov; 384(9957):1849-1858. PubMed ID: 25002178
[TBL] [Abstract][Full Text] [Related]
9. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention.
Busch G; Steppich B; Sibbing D; Braun SL; Stein A; Groha P; Schömig A; Kastrati A; von Beckerath N; Ott I
Thromb Haemost; 2009 Feb; 101(2):340-4. PubMed ID: 19190819
[TBL] [Abstract][Full Text] [Related]
10. Unfractionated heparin versus bivalirudin in patients undergoing primary percutaneous coronary intervention: a SWEDEHEART study.
Grimfjärd P; Erlinge D; Koul S; Lagerqvist B; Svennblad B; Varenhorst C; James SK
EuroIntervention; 2017 Mar; 12(16):2009-2017. PubMed ID: 28044990
[TBL] [Abstract][Full Text] [Related]
11. Use of low-dose heparin with bivalirudin for ad-hoc transradial coronary interventions: experience from a single center.
Singh A; Edasery D; Noor A; Bhasin N; Kaplan B; Jauhar R
J Invasive Cardiol; 2011 Mar; 23(3):101-4. PubMed ID: 21364238
[TBL] [Abstract][Full Text] [Related]
12. The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy.
Gurm HS; Rajagopal V; Bhatt DL; Ellis SG; Lincoff AM
J Invasive Cardiol; 2007 May; 19(5):225-8. PubMed ID: 17476038
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin: role in current percutaneous coronary intervention practice.
West N
Br J Hosp Med (Lond); 2005 Dec; 66(12):687-9. PubMed ID: 16417115
[No Abstract] [Full Text] [Related]
15. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin.
Eslam RB; Reiter N; Kaider A; Eichinger S; Lang IM; Panzer S
Eur Heart J; 2009 Aug; 30(15):1831-6. PubMed ID: 19468011
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of bivalirudin in the cardiac catheterization laboratory.
Thompson KA; Philip KJ; Schwarz ER
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):140-9. PubMed ID: 21097669
[TBL] [Abstract][Full Text] [Related]
17. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
[TBL] [Abstract][Full Text] [Related]
18. Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention.
Iijima R; Ndrepepa G; Mehilli J; Byrne RA; Schulz S; Neumann FJ; Richardt G; Berger PB; Schömig A; Kastrati A
Eur Heart J; 2009 Feb; 30(3):290-6. PubMed ID: 19147609
[TBL] [Abstract][Full Text] [Related]
19. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.
Bittl JA; Strony J; Brinker JA; Ahmed WH; Meckel CR; Chaitman BR; Maraganore J; Deutsch E; Adelman B
N Engl J Med; 1995 Sep; 333(12):764-9. PubMed ID: 7643883
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
